Respiratory tract infection

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET

Retrieved on: 
Monday, November 21, 2022

(NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2022.

Key Points: 
  • (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2022.
  • For the twelve months ended September 30, 2022, total revenue was $86.2 million compared to $97.1 million for the same period in 2021.
  • For the twelve months ended September 30, 2022, research and development expenses were $164.5 million compared to $174.1 million in 2021.
  • For the twelve months ended September 30, 2022, general and administrative expenses were $45.5 million compared to $32.5 million in 2021.

Global Point Of Care Diagnostics Market 2022: Developments Including AI Integration Drive Sector Forward - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 10, 2022

The "Global Point Of Care Diagnostics Market, By Product type, By End users, By Platform- Forecast and Analysis 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Point Of Care Diagnostics Market, By Product type, By End users, By Platform- Forecast and Analysis 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The increase in the prevalence of chronic and infectious diseases in developing economies is one of the point of care diagnostics market growth factor.
  • Global Point of Care Diagnostics Market is segmented based on product type, end users, and platform.
  • Based on end users, global point of care diagnostics market is further segmented into clinics, hospitals, homecare, assisted living healthcare facilities, laboratory.

Point-Of-Care Molecular Diagnostics Global Market Report 2022: Featuring Abbott, F Hoffmann-La Roche, BioMerieux, Danaher & Quidel - ResearchAndMarkets.com

Retrieved on: 
Monday, October 31, 2022

The "Point-Of-Care Molecular Diagnostics Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Point-Of-Care Molecular Diagnostics Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The regions covered in the point-of-care molecular diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The rapid growth in the occurrence of infectious and respiratory diseases is expected to significantly contribute to the growth of the point-of-care molecular diagnostics market.
  • Major companies operating in the point-of-care molecular diagnostics market are focused on providing technologically advanced solutions to strengthen their market position.

Enanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus

Retrieved on: 
Monday, October 3, 2022

In previous clinical studies, EDP-938 significantly improved the percentage of people with undetectable RSV RNA at the end of treatment, consistent with inhibiting viral replication.

Key Points: 
  • In previous clinical studies, EDP-938 significantly improved the percentage of people with undetectable RSV RNA at the end of treatment, consistent with inhibiting viral replication.
  • As we progress this study and advance our pipeline, we look forward to continuing to build our leadership position in this disease area.
  • The Phase 2b, randomized, double-blind, placebo-controlled, multi-center, global study is designed to evaluate the effect of EDP-938 compared with placebo on the progression of RSV infection by assessment of clinical symptoms.
  • Enantas research and development programs include clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV).

Savara Presented Data at the European Respiratory Society (ERS) International Congress 2022

Retrieved on: 
Tuesday, September 6, 2022

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented three posters at the ERS International Congress 2022 that took place September 4-6th in Barcelona, Spain.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented three posters at the ERS International Congress 2022 that took place September 4-6th in Barcelona, Spain.
  • Additionally, patients reported improved health status, as measured by St. Georges Respiratory Questionnaire-Total and -Activity, when compared with placebo-treated patients .
  • Abstract #1154: Safety and Tolerability of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) presented by F. Bonella, M.D., Ph.D.
  • Additionally, the posters are scheduled to be published in a supplement of the European Respiratory Journal (ERJ) by the end of November 2022.

Impact of Antimicrobial Stewardship Intervention in Conjunction with Rapid Multiplex Respiratory Diagnostics, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, August 23, 2022

TORONTO, Aug. 23, 2022  /PRNewswire-PRWeb/ -- Respiratory tract infections (RTIs) are the leading cause of death from infectious disease and the most common reason for empiric antimicrobial use in the US. Viruses are the causative pathogen in half to two-thirds of patients hospitalized with an RTI. Therefore, rapid identification of viral etiologies and differentiating them from bacterial can improve patient management and lead to optimized antibacterial and antiviral use, assist with decisions on hospital admission and infection control and improve clinical and economic outcomes.

Key Points: 
  • Attendees will learn about the importance of time to effective and optimal antimicrobial therapy and how RDTs can affect these crucial metrics.
  • The featured speaker will review published data regarding the impact of RTI RDTs on clinical, economic and antimicrobial stewardship (AMS) metrics.
  • Among the many tried-and-true AMS intervention strategies, the use of rapid diagnostic tests (RDTs) has quickly established itself as one of the most impactful.
  • For more information, or to register for this event, visit Impact of Antimicrobial Stewardship Intervention in Conjunction with Rapid Multiplex Respiratory Diagnostics.

Global Procalcitonin Tests (In Vitro Diagnostics) Market Analysis and Forecasts, 2015-2021 & 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 10, 2022

The "Procalcitonin Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Procalcitonin Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.
  • Procalcitonin Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
  • CMO executives who must have deep understanding of the Procalcitonin Tests market place to make strategic planning and investment decisions.
  • Track device sales in the global and country-specific Procalcitonin Tests market from 2015-2030.

Episcopal Relief & Development Responds to Civil Unrest and the COVID-19 Pandemic in South Sudan

Retrieved on: 
Thursday, April 28, 2022

NEW YORK, April 28, 2022 /PRNewswire-PRWeb/ -- Episcopal Relief & Development is supporting the South Sudanese Development and Relief Agency (SSUDRA) of the Episcopal Church of South Sudan as it responds to recent civil unrest and the COVID-19 pandemic. In collaboration with the Diocese of Salisbury and Christian Aid, SSUDRA is providing assistance to families in northwest South Sudan who have been impacted by the violence. The Church is also implementing COVID-19 educational campaigns in the central part of the country.

Key Points: 
  • Episcopal Relief & Development is supporting the South Sudanese Development and Relief Agency (SSUDRA) of the Episcopal Church of South Sudan as it responds to recent civil unrest and the COVID-19 pandemic.
  • NEW YORK, April 28, 2022 /PRNewswire-PRWeb/ -- Episcopal Relief & Development is supporting the South Sudanese Development and Relief Agency (SSUDRA) of the Episcopal Church of South Sudan as it responds to recent civil unrest and the COVID-19 pandemic.
  • Episcopal Relief & Development has a long-standing relationship with the Episcopal Church of South Sudan.
  • ABOUT EPISCOPAL RELIEF & DEVELOPMENT:
    For more than 80 years, Episcopal Relief & Development has been working together with supporters and partners for lasting change around the world.

Global Air Purifier Market Analysis Report 2022: A $25.97 Billion Industry by 2030 - HEPA Segment Held the Largest Revenue Share of Over 40% in 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 26, 2022

The "Air Purifier Market Size, Share & Trends Analysis Report by Technology (HEPA, Activated Carbon, Ionic Filters), by Application (Commercial, Residential, Industrial), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Air Purifier Market Size, Share & Trends Analysis Report by Technology (HEPA, Activated Carbon, Ionic Filters), by Application (Commercial, Residential, Industrial), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • Air purifiers assist in eliminating various health hazards caused by poor air quality by removing contaminants, including dust, smoke, and pollen.
  • This has prompted consumers to buy air purifiers and is likely to augment the market growth over the forecast period.
  • The pandemic provided an opportunity for companies with higher cashflows to acquire air purifier companies resulting in increased activity in the market.

Novadiscovery announces Nature Communications paper on modeling the disruption to respiratory clinical trials due to mitigation measures against COVID-19

Retrieved on: 
Wednesday, April 13, 2022

Lyon, France 13 April 2022: Novadiscovery (NOVA), a leading health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development, today announces the publication of a novel model of respiratory tract infections (RTI) in Nature Communications to address the uncertainties resulting from non-pharmaceutical interventions (NPIs) against COVID-19 on clinical trials.

Key Points: 
  • Lyon, France 13 April 2022: Novadiscovery (NOVA), a leading health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development, today announces the publication of a novel model of respiratory tract infections (RTI) in Nature Communications to address the uncertainties resulting from non-pharmaceutical interventions (NPIs) against COVID-19 on clinical trials.
  • The paper was published in collaboration with NOVAs partner OM Pharma.
  • Franois-Henri Boissel, CEO, NOVA said: The pandemic and all related measures such as lockdowns seriously affected clinical trials in all indications but the impact of reduced viral transmission and resulting seasonal disease pattern disruption on respiratory trials was particularly marked.
  • The authors also warned that eligibility criteria for patients into trials will need to be reassessed as disease burden has been impacted by pandemic measures.